ロード中...
Regression of brain metastases from breast cancer with eribulin: a case report
BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3878316/ https://ncbi.nlm.nih.gov/pubmed/24350786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-541 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|